{"id":40888,"date":"2025-09-08T14:56:09","date_gmt":"2025-09-08T06:56:09","guid":{"rendered":"https:\/\/flcube.com\/?p=40888"},"modified":"2025-09-08T14:56:10","modified_gmt":"2025-09-08T06:56:10","slug":"regenelead-secures-nmpa-approval-for-rgl%e2%80%91305-cell-therapy-in-advanced-malignant-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40888","title":{"rendered":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors"},"content":{"rendered":"\n<p>On <strong>September 2,\u202f2025<\/strong>, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product <strong>RGL\u2011305 Injection<\/strong> received <strong>implied clinical\u2011trial approval<\/strong> from the <strong>National Medical Products Administration (NMPA)<\/strong> of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-platform-driven-success\">Platform\u2011Driven Success<\/h3>\n\n\n\n<p><strong>RGL\u2011305<\/strong> is built upon Regenelead\u2019s proprietary <strong>Cell Therapy Platform<\/strong>, which offers:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Benefit<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Universal applicability<\/strong><\/td><td>Works across multiple tumor types<\/td><td>Broadens therapeutic scope<\/td><\/tr><tr><td><strong>High\u2011efficiency processes<\/strong><\/td><td>Accelerates cell\u2011culture timelines<\/td><td>Reduces development time<\/td><\/tr><tr><td><strong>Large\u2011scale production<\/strong><\/td><td>Supports mass manufacturing<\/td><td>Lowers per\u2011treatment cost<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The platform\u2019s robust process development, manufacturing, and quality\u2011control capabilities have enabled the company to demonstrate a scalable, cost\u2011effective production model\u2014critical for translating cell\u2011therapy innovations into real\u2011world clinical settings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-economic-amp-clinical-implications\">Economic &amp; Clinical Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Reduction<\/strong> \u2013 The efficient manufacturing pipeline is projected to cut the cost per treatment, potentially expanding access to patients across China\u2019s diverse healthcare landscape.<\/li>\n\n\n\n<li><strong>Rapid Deployment<\/strong> \u2013 With the NMPA\u2019s implied approval, Regenelead can move swiftly into early\u2011phase clinical trials, accelerating the timeline from bench to bedside.<\/li>\n\n\n\n<li><strong>Patient Reach<\/strong> \u2013 The platform\u2019s adaptability positions RGL\u2011305 to target a wide spectrum of advanced cancers, offering new therapeutic options where few exist.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-looking-ahead\">Looking Ahead<\/h3>\n\n\n\n<p>Regenelead plans to initiate multi\u2011center phase\u2011I studies later in 2025, focusing on efficacy and safety in patients with advanced solid tumors. The company\u2019s leadership also outlines plans to leverage the platform for future cell\u2011therapy candidates, aiming to establish a diversified oncology portfolio.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h3>\n\n\n\n<p>Regenelead\u2019s <strong>RGL\u2011305<\/strong> marks a pivotal moment for China\u2019s cell\u2011therapy landscape, combining cutting\u2011edge science with an industrial\u2011scale production model. The NMPA\u2019s approval not only validates the product\u2019s clinical promise but also underscores the company\u2019s commitment to delivering affordable, high\u2011quality cancer care.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40890,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,77,4339],"class_list":["post-40888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-cell-therapy","tag-regenelead"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40888\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors\" \/>\n<meta property=\"og:description\" content=\"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40888\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T06:56:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-08T06:56:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors\",\"datePublished\":\"2025-09-08T06:56:09+00:00\",\"dateModified\":\"2025-09-08T06:56:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0807.webp\",\"keywords\":[\"Cancer\",\"Cell-therapy\",\"Regenelead\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40888#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40888\",\"name\":\"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0807.webp\",\"datePublished\":\"2025-09-08T06:56:09+00:00\",\"dateModified\":\"2025-09-08T06:56:10+00:00\",\"description\":\"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40888\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0807.webp\",\"width\":1080,\"height\":608,\"caption\":\"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40888#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40888","og_locale":"en_US","og_type":"article","og_title":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors","og_description":"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.","og_url":"https:\/\/flcube.com\/?p=40888","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-08T06:56:09+00:00","article_modified_time":"2025-09-08T06:56:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40888#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40888"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors","datePublished":"2025-09-08T06:56:09+00:00","dateModified":"2025-09-08T06:56:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40888"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","keywords":["Cancer","Cell-therapy","Regenelead"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40888#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40888","url":"https:\/\/flcube.com\/?p=40888","name":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40888#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","datePublished":"2025-09-08T06:56:09+00:00","dateModified":"2025-09-08T06:56:10+00:00","description":"On September 2,\u202f2025, Shanghai\u2011based Regenelead announced that its internally developed cell\u2011therapy product RGL\u2011305 Injection received implied clinical\u2011trial approval from the National Medical Products Administration (NMPA) of China. The approval authorizes RGL\u2011305 for use in advanced malignant tumors, marking a significant milestone in the company\u2019s pursuit of next\u2011generation cancer therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40888#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40888"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40888#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","width":1080,"height":608,"caption":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40888#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regenelead Secures NMPA Approval for RGL\u2011305 Cell Therapy in Advanced Malignant Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0807.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40888"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40888\/revisions"}],"predecessor-version":[{"id":40891,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40888\/revisions\/40891"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40890"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}